Who are NVA237 200 µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Solifenacin PO, Spiriva HandiHaler, Drug: ipratropium (AtroventTM), Oxybutynin chloride, extended-release, salbutamol + ipratropium bromide nebules, Albuterol, ipratropium bromide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nva237-200-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

NVA237 200 µg — Competitive Intelligence Brief

NVA237 200 µg (NVA237 200 µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic antagonist. Area: Respiratory.

phase 2 Muscarinic antagonist M3 muscarinic acetylcholine receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

NVA237 200 µg (NVA237 200 µg) — Novartis. NVA237 is a long-acting muscarinic antagonist that blocks the M3 muscarinic acetylcholine receptor in the airways, leading to bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NVA237 200 µg TARGET	NVA237 200 µg	Novartis	phase 2	Muscarinic antagonist	M3 muscarinic acetylcholine receptor
Solifenacin PO	Solifenacin PO	Seattle Urology Research Center	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
Spiriva HandiHaler	Spiriva HandiHaler	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic acetylcholine receptor
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor
Oxybutynin chloride, extended-release	Oxybutynin chloride, extended-release	US Department of Veterans Affairs	marketed	Anticholinergic agent	M3 muscarinic acetylcholine receptor
salbutamol + ipratropium bromide nebules	salbutamol + ipratropium bromide nebules	Imperial College London	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)
Albuterol, ipratropium bromide	Albuterol, ipratropium bromide	Children's Hospital of Philadelphia	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor; M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic antagonist class)

AstraZeneca · 1 drug in this class
Henan University of Traditional Chinese Medicine · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NVA237 200 µg — Competitive Intelligence Brief. https://druglandscape.com/ci/nva237-200-g. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab